Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 18, 2020 / 12:00PM GMT
Release Date Price: kr240 (+0.67%)
Christine Hofmeister;SÃ;ren Tulstrup;publ
Morgan Stanley - VP;Hansa Biopharma AB

Hello, everyone. I'm Christine Hofmeister, a member of the European investment banking team at Morgan Stanley. And it's my great pleasure today to welcome Søren Tulstrup, the CEO of Hansa Biopharma, to our fireside chat today.

Before we kick off, I just need to read a quick disclaimer so please bear with me. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you're a member of the press, please disconnect and reach out separately.

For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

With that, Søren, welcome to the session. It would be great if you could give us a quick introduction to Hansa and the story as it stands now. So I'm happy to hand over to you.

¸ - ()

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot